Evidence map›Paper›PMID 42725478›Full record

ArticleAdvanced healthcare materials2026

Engineered Nanoplatforms Targeting Activated Hepatic Stellate Cells for Liver Fibrosis Therapy via TGF-β Axis Inhibition and Ferroptosis Induction.

Yinuo Yang, Mengyao Mu, Ke Ren, Hui Liu, Pengju Ma, Yingqi Wang, Mengmeng Zhang, Xueli Xu, Wenzhe Li, Wenshuang Gao and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yinuo YangShandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Ji'nan, Shandong, China.ORCID https://orcid.org/0000-0002-7043-474X
Mengyao MuShandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Ji'nan, Shandong, China.
Ke RenShandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Ji'nan, Shandong, China.
Hui LiuShandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Ji'nan, Shandong, China.
Pengju MaShandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Ji'nan, Shandong, China.
Yingqi WangShandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Ji'nan, Shandong, China.
Mengmeng ZhangShandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Ji'nan, Shandong, China.
Xueli XuSchool of Science, Shandong Jianzhu University, Ji'nan, Shandong, China.
Wenzhe LiCentral Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Ji'nan, Shandong, China.ORCID https://orcid.org/0009-0002-6921-5184
Wenshuang GaoRehabilitation Center, Qilu Hospital of Shandong University, Ji'nan, Shandong, China.ORCID https://orcid.org/0009-0005-8462-2898
Xiao SunShandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Ji'nan, Shandong, China.ORCID https://orcid.org/0000-0001-6506-1574
Qiang ZhuShandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Ji'nan, Shandong, China.ORCID https://orcid.org/0000-0002-5843-9724

Funding

National Natural Science Foundation of China 82370618Natural Science Foundation of Shandong ZR2022QH268Natural Science Foundation of Shandong ZR2025QC872Scientific Research Cultivation Foundation of Shandong Provincial Hospital 2022FY043Shandong Provincial Key Research and Development Program (International Science and Technology Cooperation) 2025KJHZ045
6 · The paper itself

Abstract

Liver fibrosis and its terminal stage, cirrhosis, represent a major cause of morbidity and mortality related to hepatic pathologies. Activated hepatic stellate cells (aHSCs) are the principal drivers of fibrogenesis and therefore constitute key therapeutic targets. Lanifibranor, a pan-peroxisome proliferator-activated receptor agonist, has shown promising antifibrotic efficacy; however, its clinical application is limited by rapid systemic clearance and insufficient accumulation in fibrotic liver tissue. In this study, we report an aHSC-targeted nanoplatform for lanifibranor delivery based on vitamin A-functionalized two-dimensional iron sulfide nanosheets (FeS-V

Indexed as

FerroptosisHepatic Stellate CellsLiver CirrhosisTransforming Growth Factor betaAnimalsHumansMaleMiceSignal TransductionSmad2 ProteinSmad3 ProteinSmad2 ProteinSmad3 ProteinTransforming Growth Factor betaferroptosishepatic stellate cellslanifibranorliver fibrosisTGF‐β signaling axis

Identifiers

PMID42725478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.